Wenbin Jiang Sells 20,000 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock

Cytek Biosciences, Inc. (NASDAQ:CTKBGet Rating) CEO Wenbin Jiang sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 7th. The stock was sold at an average price of $12.89, for a total transaction of $257,800.00. Following the transaction, the chief executive officer now owns 7,825,820 shares in the company, valued at $100,874,819.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Wenbin Jiang also recently made the following trade(s):

  • On Monday, August 8th, Wenbin Jiang sold 20,000 shares of Cytek Biosciences stock. The stock was sold at an average price of $15.09, for a total transaction of $301,800.00.
  • On Thursday, July 7th, Wenbin Jiang sold 20,000 shares of Cytek Biosciences stock. The stock was sold at an average price of $11.19, for a total transaction of $223,800.00.

Cytek Biosciences Stock Performance

Shares of NASDAQ CTKB opened at $14.10 on Friday. The firm has a market capitalization of $1.90 billion, a P/E ratio of -705.00 and a beta of 0.53. Cytek Biosciences, Inc. has a one year low of $7.38 and a one year high of $28.70. The company’s fifty day moving average is $12.83 and its two-hundred day moving average is $11.37.

Cytek Biosciences (NASDAQ:CTKBGet Rating) last issued its earnings results on Wednesday, August 10th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.02 by $0.01. Cytek Biosciences had a negative net margin of 1.28% and a positive return on equity of 0.62%. On average, sell-side analysts forecast that Cytek Biosciences, Inc. will post 0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Parkwood LLC raised its stake in shares of Cytek Biosciences by 44.3% during the 2nd quarter. Parkwood LLC now owns 42,292 shares of the company’s stock worth $42,000 after buying an additional 12,981 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Cytek Biosciences by 64.1% during the 1st quarter. Royal Bank of Canada now owns 5,995 shares of the company’s stock worth $65,000 after buying an additional 2,341 shares during the last quarter. Metropolitan Life Insurance Co NY raised its stake in shares of Cytek Biosciences by 31.5% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 6,415 shares of the company’s stock worth $69,000 after buying an additional 1,536 shares during the last quarter. Lazard Asset Management LLC acquired a new position in shares of Cytek Biosciences during the 2nd quarter worth $70,000. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Cytek Biosciences by 514.7% during the 1st quarter. Ameritas Investment Partners Inc. now owns 7,567 shares of the company’s stock worth $82,000 after buying an additional 6,336 shares during the last quarter. Institutional investors and hedge funds own 43.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on CTKB shares. Piper Sandler lifted their price objective on shares of Cytek Biosciences from $12.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, August 17th. The Goldman Sachs Group lifted their price objective on shares of Cytek Biosciences from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Thursday, August 11th. Finally, Morgan Stanley lifted their price objective on shares of Cytek Biosciences from $11.00 to $15.00 and gave the company an “equal weight” rating in a research report on Friday, August 12th.

About Cytek Biosciences

(Get Rating)

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.

Read More

Insider Buying and Selling by Quarter for Cytek Biosciences (NASDAQ:CTKB)

Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.